SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 4,665 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $23.32, for a total value of $108,787.80. Following the completion of the sale, the insider owned 206,585 shares of the company’s stock, valued at $4,817,562.20. The trade was a 2.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Anshul Maheshwari also recently made the following trade(s):
- On Tuesday, November 17th, Anshul Maheshwari sold 1,715 shares of SiBone stock. The shares were sold at an average price of $23.19, for a total value of $39,770.85.
- On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The shares were sold at an average price of $25.00, for a total value of $81,175.00.
- On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total value of $84,105.00.
- On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
- On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total value of $60,321.24.
- On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
- On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
SiBone Stock Up 1.6%
Shares of SIBN traded up $0.38 during trading hours on Wednesday, reaching $23.54. The company’s stock had a trading volume of 1,120,107 shares, compared to its average volume of 644,914. The company has a 50 day moving average of $20.56 and a two-hundred day moving average of $16.85. The company has a quick ratio of 6.15, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -75.93 and a beta of 0.64. SiBone has a 1-year low of $11.48 and a 1-year high of $25.92.
SiBone (NASDAQ:SIBN – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The business had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. As a group, research analysts predict that SiBone will post -0.34 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its holdings in SiBone by 9.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 483,029 shares of the company’s stock worth $9,081,000 after purchasing an additional 41,117 shares during the last quarter. Entropy Technologies LP bought a new stake in SiBone during the third quarter worth approximately $768,000. Pathstone Holdings LLC bought a new stake in SiBone during the third quarter worth approximately $346,000. Marshall Wace LLP grew its holdings in SiBone by 1.2% during the third quarter. Marshall Wace LLP now owns 698,416 shares of the company’s stock valued at $13,130,000 after purchasing an additional 8,128 shares during the last quarter. Finally, Royce & Associates LP grew its holdings in SiBone by 15.7% during the third quarter. Royce & Associates LP now owns 457,088 shares of the company’s stock valued at $8,593,000 after purchasing an additional 62,000 shares during the last quarter. 98.11% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. TD Cowen upped their target price on SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Needham & Company LLC dropped their price target on shares of SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Truist Financial raised their price target on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, Wall Street Zen raised shares of SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.
Get Our Latest Stock Analysis on SIBN
About SiBone
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
Further Reading
- Five stocks we like better than SiBone
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
